Abdel-Rahman O - Search Results

1

Prediagnostic BMI and thyroid cancer incidence in the PLCO trial.

Abdel-Rahman O. Abdel-Rahman O. Future Oncol. 2019 Oct;15(30):3451-3456. doi: 10.2217/fon-2019-0292. Future Oncol. 2019. PMID: 31646903

2

Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma.

Abdel-Rahman O, Abdel-Wahab M, Shaker M, Abdel-Wahab S, Elbassiony M, Ellithy M. Abdel-Rahman O, et al. Med Oncol. 2013;30(3):655. doi: 10.1007/s12032-013-0655-z. Epub 2013 Jul 4. Med Oncol. 2013. PMID: 23824645 Clinical Trial.

3

Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.

Abdel-Rahman O, Fouad M. Abdel-Rahman O, et al. Future Oncol. 2014 Oct;10(12):1981-92. doi: 10.2217/fon.14.42. Future Oncol. 2014. PMID: 25386814 Review.

4

Insulin-like growth factor pathway aberrations and gastric cancer; evaluation of prognostic significance and assessment of therapeutic potentials.

Abdel-Rahman O. Abdel-Rahman O. Med Oncol. 2015 Jan;32(1):431. doi: 10.1007/s12032-014-0431-8. Epub 2014 Dec 9. Med Oncol. 2015. PMID: 25487446 Review.

5

Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: a meta-analysis.

Abdel-Rahman O, Fouad M. Abdel-Rahman O, et al. Future Oncol. 2015;11(1):79-90. doi: 10.2217/fon.14.136. Future Oncol. 2015. PMID: 25572784

6

Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis.

Abdel-Rahman O, Fouad M. Abdel-Rahman O, et al. Expert Rev Anticancer Ther. 2015 Apr;15(4):465-75. doi: 10.1586/14737140.2015.1014035. Epub 2015 Feb 9. Expert Rev Anticancer Ther. 2015. PMID: 25664933 Review.

7

Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis.

Abdel-Rahman O, Elhalawani H. Abdel-Rahman O, et al. Future Oncol. 2015;11(7):1109-22. doi: 10.2217/fon.15.16. Future Oncol. 2015. PMID: 25804125

8

Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature.

Abdel-Rahman O, Fouad M. Abdel-Rahman O, et al. Future Oncol. 2015;11(8):1275-90. doi: 10.2217/fon.14.302. Future Oncol. 2015. PMID: 25832882 Review.

9

Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review.

Abdel-Rahman O, Fouad M. Abdel-Rahman O, et al. Future Oncol. 2015;11(12):1829-43. doi: 10.2217/fon.15.33. Future Oncol. 2015. PMID: 26075449 Review.

10

Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis.

Abdel-Rahman O, ElHalawani H, Fouad M. Abdel-Rahman O, et al. Future Oncol. 2015;11(17):2471-84. doi: 10.2217/fon.15.118. Epub 2015 Aug 14. Future Oncol. 2015. PMID: 26274495 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results